$2.84
Today
as of Jul 22, 16:51 ET
Last 30 days
Recent Press Releases & News
Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent "Computational Biologist" That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer
Lantern Pharma Says Longer LP-300 Treatment Helped Lung Cancer Patients in Phase 2 Study
Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer
Overview
52-week range
$1.11
$5.74
37% of range
Avg surprise (last 1)
+24.5%
Avg reaction (last 2)
-2.3%
50% positive
Latest IV / EM
1106%
EM ±122.2% · $4 · Jul 17
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Fri May 15, 2026 | Mar/2026 | $-0.30 | — | — | +28.6% | +0.3% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.39 | — | — | — | — | financials |
| Wed Aug 13, 2025 | Jun/2025 | $-0.40 | $-0.53 | +24.5% | — | — | earnings |
| Thu May 15, 2025 | Mar/2025 | $-0.42 | — | — | — | -4.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.42 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.46 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.51 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.29 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.44 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 12, 2026 | Jun/2026 | OTHER | — | -$0.40 |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-3M | — | $-4M | $-5M | $-5M | — | $-5M | $-5M |
| Net income | $-3M | — | $-4M | $-4M | $-5M | — | $-5M | $-5M |
| EPS (diluted) | $-0.30 | — | $-0.39 | $-0.40 | $-0.42 | — | $-0.42 | $-0.46 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $5M | $4M | $8M | $6M | $6M | $8M | $8M | $13M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $7M | $11M | $13M | $17M | $21M | $25M | $30M | $35M |
| Total assets | $7M | $11M | $14M | $17M | $21M | $26M | $30M | $36M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $4M | $5M | $4M | $5M | $4M | $4M | $4M | $5M |
| Total equity | $3M | $7M | $10M | $13M | $17M | $21M | $27M | $31M |